DataMeds AI Agrees To Acquire Certain Assets From Estate Of Todos Medical, Terms Undisclosed
Benzinga Newsdesk 10 hours ago
NewsM&A
CLIA-Certified Cancer Diagnostics Laboratory Will Acquire Spectroscopy Platform to Support Machine Learning Expansion into Additional Cancer TypesCE Marks previously held in Europe for breast cancer and colorectal
CLIA-Certified Cancer Diagnostics Laboratory Will Acquire Spectroscopy Platform to Support Machine Learning Expansion into Additional Cancer Types
- CE Marks previously held in Europe for breast cancer and colorectal cancer tests
- Spectroscopy platform to be transferred to Helomics to revalidate data correlations with biopsies and imaging and support LDT launch prior to FDA submissions
- Issued patents in the U.S. and Europe provide exclusivity into at least 2034
TAMPA, FL / ACCESS Newswire / November 19, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMeds AI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare technology company that integrates its physical pharmaceutical, laboratory and telemedicine infrastructures with its EinsteinRx™ Healthcare AI technology-powered digital platform, today announced that it has agreed to acquire certain assets from the estate of Todos Medical Ltd., including its Cancer Artificial Intelligence ("Cancer AI") Total Biochemical Infrared Analysis ("TBIA") blood tests for breast cancer (TM-B1 and TM-B2) and colorectal cancer (TM-C1), originally developed at Ben Gurion University (BGU) in Israel.
The TBIA Cancer AI blood testing platform leverages Fourier-transform infrared (FTIR) spectroscopy biochemical analysis of blood plasma and peripheral blood mononuclear cell (PBMC) components to distinguish between healthy subjects and patients with cancer.
